Objectives: Plasmid pB1000 bearing bla ROB-1 is responsible for high-level b-lactam resistance in Haemophilus influenzae as well as in Pasteurella multocida and Haemophilus parasuis isolates from Spain. Here, we explore the presence of ROB-1 in Italy and investigate the relative contribution of penicillin-binding protein 3 (PBP3) mutations and ROB-1 to the b-lactam resistance phenotype in H. influenzae.
Introduction
Haemophilus influenzae is a Gram-negative bacillus usually involved in community-acquired respiratory tract infections, acute otitis media, acute sinusitis and meningitis in both children and adults.
1 b-Lactam antibiotics are used for the treatment of diseases caused by this pathogen. 1 Resistance to b-lactam antibiotics in H. influenzae is conferred either by production of b-lactamases or by mutations in the ftsI gene encoding penicillin-binding protein 3 (PBP3), or by a combination of both mechanisms. Currently, two different b-lactamases are documented in H. influenzae, ROB-1 and TEM-1. These enzymes confer similar susceptibility profiles, characterized by high-level resistance to ampicillin and other aminopenicillins; in addition, ROB-1 also confers resistance to cefaclor. 2 Mutations in PBP3 are responsible for low-level resistance or reduced susceptibility to both b-lactams and combinations of b-lactams and b-lactamases inhibitors. 1 Thus, H. influenzae strains bearing both resistance mechanisms are designated as b-lactamasepositive amoxicillin/clavulanic acid-resistant (BLPACR) strains, and are becoming more prevalent. 3 However, the specific contribution of each resistance mechanism to the final BLPACR phenotype has not been clarified.
Recently, the presence of plasmid pB1000 bearing bla ROB-1 in non-related clinical isolates of H. influenzae has been reported. 2 This plasmid was first described in animal Pasteurellaceae. 4, 5 Previous analyses support the idea that pB1000 has spread among Pasteurellaceae family species in Spain. 2 Here, we describe the presence of pB1000 in a non-typeable BLPACR H. influenzae isolated in Italy in 2008, showing that pB1000 is present in other countries in Europe. Further, we characterize the relative contribution of pB1000 and PBP3 mutations to the b-lactam resistance phenotype using an isogenic environment. 
Materials and methods

DNA analysis and transformation experiments
PCR, plasmid DNA extraction, automated sequencing, sequence analysis and pB1000 PCR mapping and stability analysis were performed as described previously. 5 Primers used for ftsI amplification were ftsI-fw (5 ′ -CGATACTTTTGAGCCAGGTTC-3 ′ ) and ftsI-rev (5 ′ -TTGATTCTTGTGTTCG CCAAT-3 ′ ). The genetic relatedness of H. influenzae isolates was determined by PFGE. 7 H. influenzae Rd KW20 electrocompetent cell preparation and plasmid electroporation was carried out as previously specified. 2 Transformation of the ftsI gene from BB1059 into H. influenzae Rd KW20 was performed essentially according to Barcak et al.: 8 1 mg of purified ftsI PCR product from BB1059 was mixed with 2 mL of early logphase cells in HTM and grown overnight at 378C with 5% CO 2 . Transformants were selected on chocolate agar plates containing 0.01 mg/L cefotaxime.
Results and discussion
BLPACR high-level cefaclor-resistant clinical isolate bearing pB1000 in Italy One hundred and one invasive H. influenzae strains and 58 isolates from patients with cystic fibrosis were collected between 2004 and 2009 by the Italian Reference Laboratory for H. influenzae. All were screened for the presence of ROB-1. Twenty-one strains (21/159, 13.2%) were high-level resistant to amoxicillin (MIC .128 mg/L). One of them (1/159, 0.6%), BB1059, also showed resistance to cefaclor (MIC .4 mg/L). The presence of the bla ROB-1 gene in this isolate was confirmed by PCR and sequencing.
5 BB1059 was isolated from a 44-year-old man presenting with meningitis and a previous record of acute otitis media. Prior to the isolation of the strain, this patient had been treated for otitis media with amoxicillin/clavulanic acid orally, for 3 days. Strain BB1059 was found to be non-typeable or non-encapsulated by PCR capsular genotyping. b-Lactam susceptibility analysis of BB1059 revealed high-level resistance to ampicillin and cefaclor, and susceptibility to cefotaxime (Table 1) . BB1059 also showed a decrease in susceptibility to amoxicillin/clavulanic acid, presenting a two dilution increase in the MIC compared with fully susceptible strains (1 mg/L versus 0.25 mg/L), as previously reported. 1 The plasmid content of BB1059 was analysed to identify the genetic platform bearing bla ROB-1 . Plasmid preparation, plasmid digestion profile with PstI and XbaI endonucleases and PCR mapping revealed the presence of pB1000 in BB1059.
2 Additionally, the sequence of the ftsI gene from BB1059 showed several mutations responsible for five amino acid substitutions in PBP3, compared with the sequence from H. influenzae Rd KW20, as follows: I449V; N526K; V547I; N569S; and A586S. According to this sequence, BB1059 would be catalogued in group IId following the classification of Dabernat et al. 9 (I449V and N526K). The three additional substitutions (V547I, N569S and A586S) have been previously described in BLNAR H. influenzae strains from Japan. 10 In conclusion, BB1059 presented a BLPACR genotype consistent with its resistance profile ( Table 1) . This is, to our knowledge, the second description of an H. influenzae strain carrying ROB-1 in Italy, 11 although the genetic environment of bla ROB-1 in the previous description was not characterized. PFGE analysis showed no clonal relationship between BB1059 and any of the H. influenzae strains carrying pB1000 isolated recently in Spain 2 ( Figure S1 , lanes 5 -9; available as 
JAC
Supplementary data at JAC Online). These results show that clonal dissemination is not responsible for the spread of pB1000, and suggest that the plasmid is transmitted horizontally among Pasteurellaceae.
Genetic analysis of pB1000
Plasmid pB1000 bearing bla ROB-1 has been previously described in the swine pathogens Haemophilus parasuis and Pasteurella multocida, and in H. influenzae. 2,4,5 PFGE analysis has proved that the presence of pB1000 in an H. influenzae clinical isolate in Italy is not due to clonal spread ( Figure S1 ), as was the case for H. parasuis, 4 but to plasmid dissemination, as described in P. multocida. 5 To study the molecular epidemiology of this replicon the complete nucleotide sequence of pB1000 from BB1059 was obtained and compared with previously existing sequences from H. parasuis, P. multocida and H. influenzae.
2,4,5 pB1000 nucleotide identity ranged between 98.8% and 100%. The genetic distances between the plasmids were determined (Figure 1) . The results suggest that pB1000 has been circulating separately in human H. influenzae isolates and animal Pasteurellaceae in Europe in recent years, after an apparent transmission event between them. 2 Relative contribution of pB1000 and PBP3 mutations to the b-lactam resistance phenotype b-Lactam resistance phenotypes of BLPACR strains have been widely studied in clinical isolates. 1, 3 Notwithstanding this, the precise contribution of each resistance mechanism to the final phenotype in BLPACR H. influenzae is unclear. Comparing the resistance profile of clinical isolates bearing the two mechanisms with those of strains carrying each mechanism separately is not an accurate method, as the different genetic environment of each isolate might bias the interpretation of the results. Here, H. influenzae Rd KW20 has been used as an isogenic environment to study the relative contribution of pB1000, carrying bla ROB-1 , and PBP3 mutations to the b-lactam resistance phenotype of BB1059. Thus, Rd KW20 gave rise to strains showing BLNAR (BB1060), BLPAR (BB1061) and BLPACR (BB1062) genotypes by substitution of the ftsI gene with that from BB1059, by transformation with pB1000 or by combination of both modifications, respectively (Table 1) . Sequence analysis confirmed genetic replacement of the chromosomal ftsI gene, and plasmid preparation and PCR mapping were used to corroborate the presence of pB1000. PFGE of every isogenic strain presented an identical pattern ( Figure S1, lanes 1 -4) . A detailed b-lactam resistance profile of each genotype was determined (Table 1 ). In BB1060, mutated PBP3 confers a one or two dilution increase in the MICs of aminopenicillins, amoxicillin/clavulanic acid and cephalosporins compared with the parental strain. BB1061, bearing pB1000, showed high-level resistance to aminopenicillins and cefaclor, and a one dilution increase in the MICs of third-generation cephalosporins and amoxicillin/clavulanic acid. Finally, BB1062 showed the highest level of resistance. Interestingly, the b-lactam resistance profile of BB1062 was the result of adding BB1060 and BB1061 resistance levels for every b-lactam tested except for cefaclor, where the MIC remains at 64 mg/L for both BB1061 and BB1062. These data demonstrate an additive contribution of pB1000 and PBP3 mutations to the BLPACR phenotype. Hence, this combined strategy entails an adaptive advantage as it confers resistance or reduced susceptibility to a broader range of b-lactam antimicrobials than each mechanism separately.
Nucleotide sequence accession number
The nucleotide sequence of pB1000 from BB1059 has been deposited in GenBank under the accession number HM470204. Figure 1 . Genetic similarity dendrogram of plasmid pB1000. Strain numbers and species are indicated. The dendrogram was constructed using MEGA software, version 3.1, using the neighbour-joining grouping procedure with Kimura two-parameter distance measurement. Bar, genetic distance of 0.001. Note that pB1000 sequences from H. influenzae form a separate cluster (shaded in grey).
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